1115 stories
1 follower


1 Share

Charlie just turned a year old. Isnt he cute!! 
He loves to snuggle.  He’s about 16 pounds, housetrained and sweet.  
But… he kind of beats up on his brother.  Some dogs would prefer to be an only dog.  Charlie is one of them.  He is in Virginia and can only go to a home in our area of Virginia or Maryland.  
You can message me on Facebook if you are interested.  Message Potomac Valley Pekingese. Club, a Rescue. I am helping the owner find him a wonderful home.  🥰 


Read the whole story
2 days ago
Share this story


1 Share

Hennie went on vacation to the beach!    She had doggles to protect her eyes from the blowing sand.   GREAT IDEA.   They stayed on pretty well.   She enjoyed the wind, and her eyes were safe.  
Her mom Claretta took her along for the week.   Hennie was so good.   Her mom's niece went, too.   It looked like they had a great time!  
Hennie sat on the porch while Judy read.   The temperature was good most of the time.  
Hennie was good about picking just the right spot to do her business.  She preferred an area in front where there wasn't much vegetation-- much better.  No tall sea grass there.  
They watched a beautiful moon rise. 
It was a wonderful way to end the day.  
Hennie has the compromised front leg, but we believe she was born this way.   She still gets around well.  
Some days it was a little windy and blew her hair around.   But she had her doggles if it got too much.  
I'm so glad she and her mom had a time away-- to read, to have fun with her niece, and to rest.   That's what vacations are for.  💜

Read the whole story
10 days ago
Share this story


1 Share

 You know how much our Pekes like to help.   

Big boxes arrived at the house.  
Toasty and Tuk Tuk are no exceptions to helping.   Their mom bought a new porch couch.  
Tuk Tuk showed it off after it was all set up.  
He was so proud of how he did much pushing and moving everything into place.  

Granger's mom put him in the large box-- you know how much he loves boxes.  
Then, the youngsters jumped in.  Granger cannot do that.  Jumping is for young Pekes, not seniors.  
Tuk Tuk and Toasty fought over one of the paper tubes.  Granger just watched from the back of the box.    Shenanigans!

The smaller boxes came out to the porch and Tuk Tuk supervised.  
As you can imagine, his guidance was instrumental in getting everything set up correctly.  

There are cushions underneath and Granger is happy to test them out the space.  
Is this going to stay here?  
Once it was all in place, he got on the new couch (he may have had some help), he checked it out.  Perfect!  A new place to nap. 
 Granger, Tuk Tuk and Toasty are happy pups!  

Read the whole story
15 days ago
Share this story

AI Drugs So Far

1 Share

Here's a new paper whose title asks a question that's on a lot of peoples' minds these days: "How successful are AI-discovered drugs in clinical trials?" We are (very arguably) getting to the point where this question is worth asking, and the very first part of that argument is what qualifies as an AI-discovered drug.

The paper's Supplementary Material gives the details on what compounds have been included in the authors' analysis. They began with a list of AI-focused companies (114!), then matched that up with the clinical projects that are reported for them (39 of them). That list is in the SI file, and you will have definitely heard of some of these companies, but you will have definitely not have heard of some of the others. These clinical assets were binned into five categories: projects with AI-discovered targets (I), small molecules that were themselves discovered or optimized via AI techniques (II), biologics that were similarly discovered or optimized (III), vaccines similarly discovered or repurposed (IV), or drugs that have been repurposed through AI techniques (V).

The first compound in their analysis to enter clinical trials was in 2015 - I'm not sure what that was, but if I'm interpreting their color scheme in Figure 1b correctly, it was "AI-repurposed". That seems a little. . .early. . .to be calling anything AI in this field, but that entire list of companies is based on what they say that they do and how they say that they're doing it, so it's unavoidable. If you look at the 2023 figures, the authors have 24 AI-discovered targets, 22 AI-optimized small molecules, 4 antibodies, 6 vaccines, and 10 repurposed compounds. So what do we think about those figures?

My first reaction is that the idea of twenty-four AI-discovered targets is really high. So I went looking through the SI table to see which ongoing projects fell into that category and what those compounds and targets were. Here's what I found:

ATH-63, a "first-in-class, oral, small molecule, genomic regulator"

BEN-8744, a PDE10 inhibitor 

BDTX-1535, an oral EGFR inhibitor

BDTX-4933, targeting various mutant forms of BRAF

CEL-383, an anti-TREM1 antibody for IBD

Bapotulimab, an anti-ILDR2 antibody for various tumor types

HFB301001, an anti-OX40 (CD134) antibody

HFB200301, an anti-TNFR2 antibody

HFB200603, an anti-BTLA monoclonal antibody

HST-1011, a CBL-B inhibitor

HMBD-001, an anti-HER3 antibody

HMBD-002, an anti-VISTA antibody

INS018-055, a small molecule TNIK inhibitor

Omilancor, a LANCL2 activator

NX-13, an NLRX1 agonist

NIM-1324, a LANCL2 activator

NEU411, an LRRK2 inhibitor

REC-994, a superoxide scavenger

REC-3964, a C. difficile toxin B inhibitor

VRG-50635, a PIKfyve inhibitor

OK, that's what I have from the table. I have linked to a relevant site for each drug candidate and then to a relevant site about the targets involved. The only one that I can't round up enough information to be sure about is ATH-63. What you will see is that in almost every case, these targets were already known to be implicated in the disease under investigation. In some of these examples, in fact there are several drugs already in the clinic targeting the same proteins, or even therapies that are already on the market working through the same mechanisms (C. diff toxin B, e.g.) I don't think any of these are bad targets, let me make that clear. There are some really interesting things on the list, but I do not see how any of them can be classified as "target discovered by AI". I really don't. 

That colors my entire view of this paper - which was written by a prominent consulting firm, why did you ask. That extends to their analysis of success rates, which is (via the title) the apparent focus of the whole thing. They say that of the 24 therapies that have reported Phase I, 21 were successful. The industry standard success rate for Phase I is 66% for all indications and 76% for lead indications, so while the AI-based examples here might be getting through Phase I at a higher rate, both the sample size and outright differences are too small, in my opinion, to make that claim. I would also add that few (if any) of these compounds have had any laying-on-of-hands for Phase I optimization, because for the most part no one knows any AI techniques to do that specifically (to the best of my knowledge).

Meanwhile, four out of ten have succeeded in Phase II, which for what it's worth (an even smaller sample!) is exactly the same as for non-AI compounds. And frankly, this is where I'd expect the numbers to be the same, because Phase II success is all about picking the right targets, and (as mentioned above) these were all already targets that people go interested in the old-fashioned way, not because the AI picked them out of the ether and said to go for them. Why shouldn't they fail at the same rate as everybody else's stuff?

So let's watch these numbers as things evolve and come back to this topic. For now, I am not convinced that issuing press releases about your compounds that talk about their discovery through AI techniques is sufficient to expect greater things from them. I would like for that to be true, but I'm not ready to say that it is yet.

Read the whole story
24 days ago
Share this story


1 Share

Bentley was one of the #WV6.   Like the rest, he was very young. 
He was loved at the vet's office, and they all received such great care.  
He was fostered by Joe and Sonia, and they adored him.   They had previously fostered Bellamy, and his owners wanted to meet Bentley.  
He's been there several weeks and it's as if he was always there.   
He loves his new home and his new siblings,  
He has a new sister, and of course, Bellamy is now his brother.  
He is totally relaxed there.   His new human brother is young (and very good with dogs) and could not say "Bentley" so he called him Banjo-- it stuck.  
So, Banjo is home-- and loving it!  💖

Read the whole story
38 days ago
Share this story


1 Share

Just a quick post to introduce you to the West Virginia 6.  They go to their foster homes today.  All their labs have been done and now they can just relax until it’s time to spay/neuter them.   Ginger is small and we already have a lot of interest in her. 
Charlotte- well she isn’t a Peke but I wasn’t about to leave this puppy in the mountains. She has extra back toes. 😁
Sable is very timid. She needs a friend. She has leaned on her puppy friends for comfort.  She will get better in a quiet home w a friend. (Maybe someone will adopt 2.). 
Bentley is a sweet one.  He looks like he has pug in him.  Sweet boy. 
Clementine definitely has Peke in her. She’s beautiful. I love them all. 
Brock has been called “Big Daddy” at the vet.   He's a big boy at 19 pounds.  He got this nickname because  this sweet boy took care of the little ones when they were in the mountains— in an off grid area.  But someone saw them.  And she fed them.   And she contacted us and asked for help.   That’s why they are safe.  She’s a hero.  
I’ll post more but I may take a few days off.  It’s been a week. 

Read the whole story
112 days ago
Share this story
Next Page of Stories